Medivir AB Release: Positive Results From a Phase Ia Study With MIV-711 for the Treatment of Skeletal Disorders

Published: May 21, 2013

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

Stockholm, Sweden – Medivir AB (OMX:MVIR) announced that data from a first in man study on the investigational cathepsin K inhibitor MIV-711 for the treatment of osteoarthritis and osteoporosis was presented today at the European Calcified Tissue Society (ECTS) Annual Meeting in Lisbon, Portugal.

Help employers find you! Check out all the jobs and post your resume.

Back to news